Detalhe da pesquisa
1.
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Eur J Haematol
; 111(2): 311-317, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231885
2.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
3.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
4.
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
Ann Hematol
; 101(6): 1275-1282, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35318505
5.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
6.
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Eur J Haematol
; 105(3): 335-343, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32441419
7.
Second cancers in MPN: Survival analysis from an international study.
Am J Hematol
; 95(3): 295-301, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816122
8.
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Hematol Oncol
; 37(3): 291-295, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050810
9.
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Am J Hematol
; 98(8): E204-E208, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222267
10.
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Ann Hematol
; 96(3): 387-391, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27889820
11.
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Eur J Haematol
; 96(6): 643-9, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26277477
12.
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Am J Hematol
; 91(3): 318-21, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26748894
13.
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Am J Hematol
; 90(2): 125-31, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25377359
14.
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations.
Br J Haematol
; 186(4): e100-e103, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31016714
15.
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents.
Leuk Lymphoma
; 64(11): 1840-1846, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37554018
16.
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
Haematologica
; 97(11): 1731-5, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689684
17.
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
Cancers (Basel)
; 14(19)2022 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230820
18.
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
J Clin Med
; 11(9)2022 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35566719
19.
Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant.
Transfusion
; 50(2): 501-6, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19821947
20.
Extensive toxic epidermal necrolysis following brentuximab vedotin administration.
Ann Hematol
; 94(2): 355-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24981690